Multiple endocrine neoplasia type 1

* How Does FMEN1 Affect the Endocrine Glands?

* Rare Complications of FMEN1

* Are the Tumors Associated With FMEN1 Cancerous?

* Is FMEN1 the Same in Everyone?

* Can FMEN1 Be Cured?

* How Is FMEN1 Detected?

* What is the Role for Genetic Counseling with MEN1 Gene Testing?

* Why Screen for FMEN1?

* Who Should Consider MEN1 Screening?

* Should a Person Who Has FMEN1 Avoid Having Children?

* Research in FMEN1

* Additional Information

* Other Resources

Familial multiple endocrine neoplasia type 1 (FMEN1) is an inherited disorder that affects the endocrine glands. It is sometimes called familial multiple endocrine adenomatosis or Wermer's syndrome, after one of the first doctors to recognize it. FMEN1 is quite rare, occurring in about 3 to 20 persons out of 100,000. It affects both sexes equally and shows no geographical, racial, or ethnic preferences.

Endocrine glands are different from other organs in the body because they release hormones into the bloodstream. Hormones are powerful chemicals that travel through the blood, controlling and instructing the functions of various organs. Normally, the hormones released by endocrine glands are carefully balanced to meet the body's needs.

In patients with FMEN1, sometimes more than one group of endocrine glands, such as the parathyroid, the pancreas, and the pituitary become overactive at the same time. Most people who develop overactivity of only one endocrine gland do not have FMEN1.

How Does FMEN1 Affect the Endocrine Glands?

The Parathyroid Glands

The parathyroids are the endocrine glands earliest and most often affected by FMEN1. The human body normally has four parathyroid glands, which are located close to the thyroid gland in the front of the neck. The parathyroids release a chemical called parathyroid hormone, which helps maintain a normal supply of calcium in the blood, bones, and urine.

In FMEN1, all four parathyroid glands tend to be overactive. They release too much parathyroid hormone, leading to excess calcium in the blood. High blood calcium, known as hypercalcemia, can exist for many years before it is found by accident or by family screening. Unrecognized hypercalcemia can cause excess calcium to spill into the urine, leading to kidney stones or kidney damage.

Nearly everyone who inherits a susceptibility to FMEN1 will develop overactive parathyroid glands (hyperparathyroidism) by age 50, but the disorder can often be detected before age 20. Hyperparathyroidism may cause no problems for many years or it may cause problems such as tiredness, weakness, muscle or bone pain, constipation, indigestion, kidney stones, or thinning of bones.

Treatment of Hyperparathyroidism.

It is sometimes difficult to decide whether hyperparathyroidism in FMEN1 is severe enough to need treatment, especially in a person who has no symptoms. The usual treatment is an operation to remove the three largest parathyroid glands and all but a small part of the fourth. After parathyroid surgery, regular testing of blood calcium should continue, since the small piece of remaining parathyroid tissue can grow larger and cause recurrent hyperparathyroidism. People whose parathyroid glands have been completely removed by surgery must take daily supplements of calcium and vitamin D to prevent hypocalcemia (low blood calcium).

The Pancreas Gland

The pancreas gland, located behind the stomach, releases digestive juices into the intestines and releases key hormones into the bloodstream. Some hormones produced in the islet cells of the pancreas and their effects are:

* insulin--lowers blood sugar;

* glucagon--raises blood sugar;

* somatostatin--inhibits many cells.

Gastrin is another hormone that can be over secreted in FMEN1. The gastrin comes from one or more tumors in the pancreas and small intestine. Gastrin normally circulates in the blood, causing the stomach to secrete enough acid needed for digestion. If exposed to too much gastrin, the stomach releases excess acid, leading to the formation of severe ulcers in the stomach and small intestine. Too much gastrin can also cause serious diarrhea.

About one in three patients with FMEN1 has gastrin-releasing tumors, called gastrinomas. (The illness associated with these tumors is sometimes called Zollinger-Ellison syndrome.) The ulcers caused by gastrinomas are much more dangerous than typical stomach or intestinal ulcers; left untreated, they can cause rupture of the stomach or intestine and even death.

Treatment of Gastrinomas.

The gastrinomas associated with FMEN1 are difficult to cure by surgery, because it is difficult to find the multiple small gastrinomas in the pancreas and small intestine. In the past, the standard treatment for gastrinomas was the surgical removal of the entire stomach to prevent acid production. The mainstay of treatment is now very powerful medicines that block stomach acid release, called acid pump inhibitors. Taken by mouth, these have proven effective in controlling most cases of Zollinger-Ellison syndrome.

The Pituitary Gland

The pituitary is a small gland inside the head, behind the bridge of the nose. Though small, it produces many important hormones that regulate basic body functions. The major pituitary hormones and their effects are:

* prolactin--controls formation of breast milk, influences fertility, and influences bone strength;

* growth hormone--regulates body growth, especially during adolescence;

* adrenocorticotropin (ACTH)--stimulates the adrenal glands to produce cortisol;

* thyrotropin (TSH)--stimulates the thyroid gland to produce thyroid hormones;

* luteinizing hormone (LH)--stimulates the ovaries or testes to produce sex hormones that determine many features of "maleness" or "femaleness"; and

* follicle stimulating hormone (FSH)--regulates fertility in men through sperm production and in women through ovulation.

The pituitary gland becomes overactive in about one of four persons with FMEN1. This overactivity can usually be traced to a very small, benign tumor in the gland that releases too much prolactin, called a prolactinoma. High prolactin can cause excessive production of breast milk or it can interfere with fertility in women or with sex drive and fertility in men.

Treatment of Prolactinomas.

Most prolactinomas are small, and treatment may not be needed. If treatment is needed, a very effective type of medicine known as a dopamine agonist can lower the production of prolactin and shrink the prolactinoma. Occasionally, prolactinomas do not respond well to this medication. In such cases, surgery, radiation, or both may be needed.

Rare Complications of FMEN1

Occasionally, a person who has FMEN1 develops islet tumors of the pancreas that secrete high levels of pancreatic hormones other than gastrin. Insulinomas, for example, produce too much insulin, causing serious low blood sugar, or hypoglycemia. Pancreatic tumors that secrete too much glucagon or somatostatin can cause diabetes, and too much vasoactive intestinal peptide can cause watery diarrhea.

Other rare complications arise from pituitary tumors that release high amounts of ACTH, which in turn stimulates the adrenal glands to produce excess cortisol. Pituitary tumors that produce growth hormone cause excessive bone growth or disfigurement.

Another rare complication is an endocrine tumor inside the chest or in the stomach, known as a carcinoid. In general, surgery is the mainstay of treatment for all of these rare types of tumors, except for gastric carcinoids which usually require no treatment.

Are the Tumors Associated With FMEN1 Cancerous?

The overactive endocrine glands associated with FMEN1 may contain benign tumors, but usually they do not have any signs of cancer. Benign tumors can disrupt normal function by releasing hormones or by crowding nearby tissue. For example, a prolactinoma may become quite large in someone with FMEN1. As it grows, the tumor can press against and damage the normal part of the pituitary gland or the nerves that carry vision from the eyes. Sometimes impaired vision is the first sign of a pituitary tumor in FMEN1.

Another type of benign tumor often seen in people with FMEN1 is a plum-sized, fatty tumor called a lipoma, which grows under the skin. Lipomas cause no health problems and can be removed by simple cosmetic surgery if desired. These tumors are also fairly common in the general population.

Benign tumors do not spread to or invade other parts of the body. Cancer cells, by contrast, break away from the primary tumor and spread, or metastasize, to other parts of the body through the bloodstream or lymphatic system.

The pancreatic islet cell tumors associated with FMEN1 tend to be numerous and small, but most are benign and do not release active hormones into the blood. A proportion of pancreatic islet cell tumors in FMEN1 are cancerous.

Treatment of Pancreatic Endocrine Cancer in FMEN1.

Since the type of pancreatic endocrine cancer associated with FMEN1 can be difficult to recognize, difficult to treat, and very slow to progress, doctors have different views about the value of surgery in managing these tumors.

One approach is to "watch and wait," using medical, or nonsurgical treatments. According to this school of thought, pancreatic surgery has serious complications, so it should not be attempted unless it will cure a tumor that is secreting too much hormone.

Another school advocates early surgery, perhaps when a tumor grows to a certain size, to remove pancreatic endocrine cancer in FMEN1 (even if it does not over secrete a hormone) before it spreads and becomes dangerous. There is no clear evidence, however, that aggressive surgery to prevent pancreatic endocrine cancer from spreading actually leads to longer survival for patients with FMEN1.

Doctors agree that excessive release of certain hormones (such as gastrin) from pancreatic endocrine cancer in FMEN1 needs to be treated, and medications are often effective in blocking the effects of these hormones. Some tumors, such as insulin-producing tumors of the pancreas, are usually benign and single and are curable by pancreatic surgery. Such surgery needs to be considered carefully in each patient's case.

Is FMEN1 the Same in Everyone?

Although FMEN1 tends to follow certain patterns, it can affect a person's health in many different ways. Not only do the features of FMEN1 vary among members of the same family, but some families with FMEN1 tend to have a higher rate of prolactin-secreting pituitary tumors and a much lower frequency of gastrin-secreting tumors.

In addition, the age at which FMEN1 can begin to cause endocrine gland overfunction can differ strikingly from one family member to another. One person may have only mild hyperparathyroidism beginning at age 50, while a relative may develop complications from tumors of the parathyroid, pancreas, and pituitary by age 20.

Sometimes a patient with MEN1 knows of no other case of FMEN1 among relatives. The commonest explanations are that knowledge about the family is incomplete or that the patient carries a new MEN1 gene mutation.

Can FMEN1 Be Cured?

There is no cure for FMEN1 itself, but most of the health problems caused by FMEN1 can be recognized at an early stage and controlled or treated before they become serious problems.

If you have been diagnosed with FMEN1, it is important to get periodic checkups because FMEN1 can affect different glands, and even after treatment, residual tissue can grow back. Careful monitoring enables your doctor to adjust your treatment as needed and to check for any new disturbances caused by FMEN1.

How Is FMEN1 Detected?

Each of us has millions of genes in each of our cells, which determine how our cells and bodies function. In people with FMEN1, there is a mutation, or mistake, in one gene of every cell. A carrier is a person who has the MEN1 gene mutation. The MEN1 gene mutation is transmitted directly to a child from a parent carrying the gene mutation.

The MEN1 gene was very recently identified. As of 1998, a small number of centers around the world have begun to offer MEN1 gene testing on a research basis. The likelihood of finding a mutation in an MEN1 family has varied from 60 percent to 94 percent depending on methods. When a mutatioin is found, further testing in other relatives can become much easier. Many relatives can be tested once and be found without the known MEN1 mutation in their family, and then they can be freed from uncertainty and from any further testing ever for MEN1. When a mutation is not found in a family or isolated case, it does not prove that no MEN1 mutation is present. Depending on the clinical and laboratory information, it may still be very likely that a mutation is present but undetected.

In the meantime, though, screening of close relatives of persons with FMEN1, who are at high risk, generally involves testing for hyperparathyroidism, the most common and usually the earliest sign of FMEN1. Any doctor can screen for hyperparathyroidism by testing the blood for calcium and sometimes one or two other substances such as ionized calcium and parathyroid hormone. An abnormal result indicates that the person probably has FMEN1, but a normal finding cannot rule out the chance that he or she will develop hyperparathyroidism at a later time. Blood testing can usually show signs of early hyperparathyroidism many years before symptoms of hyperparathyroidism occur.

What is the Role for Genetic Counseling with MEN1 Gene Testing?

Genetic counseling, which should accompany the gene testing, can assist family member(s) address how the test results affect them individually and as a family. In genetic counseling, there can be a review and discussion of issues about the psychosocial benefits and risks of the genetic testing results. Genetic testing results can affect self-image, self-esteem, and individual and family identity. In genetic counseling, issues related to how and with whom genetic test results will be shared and their possible effect on important matters such as health and life insurance coverage can be reviewed and discussed. The times for these discussions can be when a family member is deciding whether or not to go ahead with the gene testing and again later when the gene testing results are available. The person, who provides the genetic counseling to the family member(s), may be a professional from the disciplines of genetics, nursing, or medicine.

Why Screen for FMEN1?

FMEN1 is not an infectious or contagious disease, nor is it caused by environmental factors. Because FMEN1 is a genetic disorder inherited from one parent, and its transmission pattern is well understood, family members at high risk for the disorder can be easily identified.

Testing can detect the blood chemical problems caused by FMEN1 many years before their later complications develop. Finding these hormonal imbalances early enables your doctor to begin preventive treatment, reducing the chances that FMEN1 will cause problems later.

Who Should Consider MEN1 Screening?

Who Should Consider MEN1 Screening by Gene Testing?

Screening may be offered to persons with MEN1 or FMEN1 or with features resembling them. Affected relatives of persons with MEN1 can be tested. Asymptomatic offspring, brothers, or sisters of a person with MEN1 were born with a 50 percent chance of having inherited the gene; they too can be offered gene testing. While gene testing can be definitive at any age, it is usually not offered to children below age 18 unless the test outcome would have an important effect on their medical treatment. Delaying the gene testing until adulthood preserves the free choice of the person to accept or refuse a test that might have important effects on their job opportunities and insurance status.

Who Should Consider MEN1 Screening by Laboratory Tests?

MEN1 screening by gene testing will be the most definitive test, when it is available. However, it is not yet widely available, and, when no gene mutation is found in a MEN1 family, then it may be necessary to rely upon laboratory tests for diagnosis. Hyperparathyroidism, most often the first sign of MEN1 or FMEN1, can usually be detected by blood tests between the ages of 15 and 50. Periodic testing should begin around age 10 and be repeated every year. There is no age at which periodic testing should stop, since doctors cannot rule out the chance that a person has inherited the MEN1 gene mutation. However, a person with normal testing beyond age 50 is very unlikely to have inherited the MEN1 gene mutation.

Should a Person Who Has FMEN1 Avoid Having Children?

A person who has FMEN1 or who has a positive MEN1 gene mutation may have a hard time deciding whether to have a child. No one can make this decision for anyone else, but some of the important facts can be summarized as follows:

* A man or a woman with FMEN1 has a 50-50 risk with each pregnancy of having a child with FMEN1.

* FMEN1 tends to fit a broad pattern within a given family, but the severity of the disorder varies widely from one family member to another. In particular, a parent's experience with FMEN1 cannot be used to predict the severity of FMEN1 in a child.

* FMEN1 is a problem that does not usually develop until adulthood. Treatment may require regular monitoring and considerable expense, but the disease usually does not prevent an active, productive adulthood.

* Prolactin-releasing tumors in a man or woman with FMEN1 may inhibit fertility and make it difficult to conceive. Also, hyperparathyroidism in a woman during pregnancy may raise the risks of complications for mother and child.

Genetic counseling can help individuals and couples through the decision-making process with family planning. Genetic counselors will provide information to help with the decision-making process, but they will not tell individuals or couples what decision to make or how to make it.

Research in FMEN1

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) was established by Congress in 1950 as part of the National Institutes of Health (NIH), whose mission is to improve human health through biomedical research. The NIH is the research arm of the Public Health Service under the U.S. Department of Health and Human Services.

The NIDDK conducts and supports a variety of research in endocrine disorders, including FMEN1. NIDDK and other NIH researchers isolated the MEN1 gene in 1997. Researchers have also shown that the MEN1 gene contributes to common endocrine tumors outside of the familial setting.

Additional Information

After reading this e-text, you may think of questions that you would like answered. Some sources of additional information are medical textbooks, physicians, nurses, and genetic counselors.

The following articles about FMEN1 can be found in medical libraries, some college and university libraries, and through interlibrary loan in most public libraries.

Chandrasekharappa, S.C., Gum, S.C., Manickam, P., Olufemi, S., Collins, F.S. Emmert-Buck, M.R., Debelenko, L.V., Zhuang, Z., Lubensky, I.A., Liotta, L.A., Crabtree, J.S., Wang, Y., Roe, B.A., Weisemann, J., Boguski, M.S., Agarwal, S.K., Kester, M.B., Kim, Y.S., Heppner, C., Dong, Q., Spiegel, A.M., Burns, A.L., Marx, S.J., "Positional cloning of the gene for multiple endocrine neoplasia-type 1," Science 276:404-407, 1997.

Friedman, E., Larsson, C., Amorosi, A., Brandi, M.L., Bale, A., Metz, D., Jensen, R.T., Skarulis, M., Eastman, R.C., Nieman, L., Norton, J.A., Marx, S.J., "Multiple endocrine neoplasia type 1: Pathology, pathophysiology, and differential diagnosis," in The Parathyroids, ed. by Bilezekian, J.P., Levine, M.A., and Marcus R. Raven Press, 1994, 647-680.

Marx, S., "Multiple endocrine neoplasia type 1" in the Genetic Basis of Human Cancer, ed by Vogelstein, B. and Kinzler, K. McGraw-Hill, 1998, 489-506.

Other Resources

The following organizations might also be able to assist with certain types of information:

Office of Scientific and Health Information National Institute of Diabetes and Digestive and Kidney Diseases Building 31, Room 9A04 Bethesda, MD 20892

March of Dimes/Birth Defects Foundation 1275 Mamaroneck Avenue White Plains, NY 10605 (914) 428-7100

Alliance for Genetic Support Groups 35 Wisconsin Circle, Suite 440 Chevy Chase, MD 20815 1-800-336-GENE or (301) 652-5553

This e-pub was written by Stephen J. Marx, M.D. and reviewed by Robert T. Jensen, M.D., both of the National Institute of Diabetes and Digestive and Kidney Diseases. It is based in part on the booklet, "Understanding Multiple Endocrine Neoplasia Type 1," published by the NIH Clinical Center's Communications Office.

This e-text is not copyrighted. NIDDK encourages users to duplicate and distribute as many copies as needed. Printed single copies may be obtained from the Office of Communications and Public Liaison, NIDDK, 31 CENTER DRIVE, MSC 2560, Bethesda, Maryland 20892-2560.

NIH Publication No. 97-3048 June 1997

e-text last updated: 11 March 1998

COPYRIGHT 1997 National Institute of Diabetes & Digestive & Kidney Diseases
COPYRIGHT 2004 Gale Group